HIGHLIGHTS
- who: Marialuisa Polillo and colleagues from the Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Pisa have published the article: Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia, in the Journal: (JOURNAL)
- what: The study proposed an increase of daily dose of imatinib to overcome the low activity of SLC22A1 . The investigation of TKI pharmacogenetics in CML patients has led to important results, with the aim to decipher the relationships between genes and drugs.
- future: A part of that variability still remains unexplained even if other approaches and areas . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.